Gilead Sciences, Inc. (GILD) · Oct 29, 2026 · Earnings

Gilead earnings beat, but acquisition charges worsen 2026 EPS guide

Beat — Non-GAAP EPS $2.55 vs ~$2.18 consensus; revenue $8.30B vs ~$7.81B

Gilead’s Q3 earnings beat revenue and adjusted EPS expectations on 18% HIV growth, while acquisition charges pushed full-year EPS guidance lower.

Gilead remains an HIV-led biopharma company, using long-acting lenacapavir to extend its prevention and treatment franchise while building out oncology and inflammation through launches, trials and acquisitions.

The quarter beat the market’s bar by a wide margin. Revenue reached $8.30 billion versus published consensus of roughly $7.81 billion, while non-GAAP diluted EPS was $2.55 versus approximately $2.18 expected. Product sales rose 13%, led by an 18% jump in HIV, with Descovy up 49% and Trodelvy up 42% year over year.

Q3 2026Q3 2025Consensus / prior guide
Total revenue (Financial Highlights)$8.30B (+6.8%)$7.77B~$7.81B
Non-GAAP diluted EPS (Non-GAAP results)$2.55 (+3.2%)$2.47~$2.18
HIV sales (Segment results — HIV)$6.25B (+18%)$5.28B
Product sales (Guidance)$31.0B–$31.3B$30.1B–$30.4B prior
Non-GAAP diluted EPS guide (Guidance)$(1.20)–$(0.85)$(0.65)–$(0.30) prior

The underlying commercial story improved, especially in HIV. Gilead raised full-year product-sales guidance by $900 million at the midpoint, and the increase is not coming from Veklury: ex-Veklury sales guidance also rose by $900 million. HIV prevention is beginning to matter financially, with Yeztugo contributing $305 million in the quarter and total HIV sales reaching $6.25 billion.

The catch is that Gilead is buying this pipeline at a heavy near-term accounting cost. Full-year non-GAAP EPS guidance was cut to a loss of $1.20–$0.85 from a loss of $0.65–$0.30, while the company says approximately $9.88 per share of the 2026 impact comes from acquired in-process R&D charges tied to the Arcellx, Tubulis, Ouro Medicines and PepStar transactions. That makes the EPS guide less useful as a measure of core operating momentum, but it also confirms that the growth strategy is consuming cash: cash and marketable securities fell to $6.4 billion from $10.6 billion at year-end after $11.3 billion of acquisition outflows.

The pipeline news adds strategic support, but not near-term revenue certainty. FDA approval of Bixlenvo strengthens the HIV franchise, while the Phase 2 emvistegrast result clears its primary endpoint and supports a planned Phase 3 start in 2027. These are meaningful additions to the growth story, but the inflammation asset remains investigational and Gilead’s oncology and cell-therapy performance is still uneven. 〔0〕 〔1〕

Bottom line: This was a real operating beat and a stronger-than-expected quarter, powered by HIV and rising base-business sales. The offset is that Gilead is paying for future growth through large acquisition charges and cash outlays, leaving the overall message mixed rather than cleanly positive.

What to watch next

Phase 3 emvistegrast study initiation in 2027

Original filing on SEC EDGAR

Gilead earnings beat, but acquisition charges worsen 2026 EPS guide | GILD Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.